Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02394769 · ClinicalTrials.gov registry record · NA

ASPirin Intervention for the REDuction of Colorectal Cancer Risk

A NA study of Colorectal Cancer, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
180
Enrollment target
1
Study location

NCT02394769: Active NA study of Colorectal Cancer, sponsored by Massachusetts General Hospital.

NCT02394769 is a NA study of Colorectal Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 180 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02394769, a NA study of Colorectal Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

This research study is investigating the use of aspirin as a potential chemopreventive agent to reduce risk of colorectal cancer

Conditions Studied

Interventions

  • DRUG Aspirin
  • DRUG Placebo for Aspirin

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2015-07-06
Est. Completion 2029-07
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT02394769

The ClinicalTrials.gov registry entry for NCT02394769 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.

NCT02394769 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02394769 about?

NCT02394769 is a clinical study titled "ASPirin Intervention for the REDuction of Colorectal Cancer Risk". This research study is investigating the use of aspirin as a potential chemopreventive agent to reduce risk of colorectal cancer

What is the current status of trial NCT02394769?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2015-07-06. Estimated completion is 2029-07.

What conditions does trial NCT02394769 study?

This clinical trial studies the following conditions: Colorectal Cancer.

What interventions are being tested in trial NCT02394769?

The interventions under investigation include: Aspirin (DRUG), Placebo for Aspirin (DRUG).

Who is sponsoring clinical trial NCT02394769?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02394769 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.